Primary course vaccination is recommended for all adults. The recommended schedule is 2 doses, 8 weeks apart. An additional (3rd) primary course dose is recommended for severely immunocompromised adults, given 8 weeks after the second dose.
A 2023 COVID-19 vaccine dose is recommended for the following groups, to be given at least 6 months after their most recent COVID-19 vaccine dose:
- All adults aged ≥65 years,
- adults aged 18 - <65 years who have medical comorbidities that increase their risk of severe COVID-19, and
- adults who have a disability with significant or complex health needs.
A 2023 dose may be considered for other adults aged 18 - <65 years, based on an individual risk-benefit assessment.
A second 2023 COVID-19 vaccine dose, is recommended for all adults aged ≥75 years if 6 months have passed since their last dose.
A second 2023 dose can be considered for adults aged 65 -<75 years and for those with severe immunocompromise. Within these groups, the second 2023 dose would be of most benefit to those who have no known history of SARS-CoV-2 infection (therefore unlikely to have hybrid immunity), who are at greater risk of severe COVID-19 due to multiple complex comorbidities, or who reside in a residential aged care facility.
People who become eligible for 2023 doses should continue to receive these doses until updated advice becomes available in early 2024.
A person may be vaccinated earlier than the recommended 6-month interval in exceptional circumstances, such as before starting immunosuppressant therapy, before overseas travel or if someone cannot reschedule vaccination easily (such as in an outreach vaccination program).
Omicron XBB.1.5-based vaccines are preferred for both primary course and further doses. Adults may receive Comirnaty Omicron XBB.1.5 ≥12 years formulation (dark grey cap) and Spikevax Omicron XBB.1.5. Comirnaty bivalent Original/Omicron BA.4/5, Spikevax bivalent Original/Omicron BA.4/5, Comirnaty bivalent Original/Omicron BA.1 and Nuvaxovid can also be used for primary or further doses but is not preferred.